Immunization with glypican-3 nanovaccine containing TLR7 agonist prevents the development of carcinogen-induced precancerous hepatic lesions to cancer in a murine model.
CONCLUSIONS: LPMan-GPC3/CL097 immunization induced de novo generation of specific T cells against tumor-associated antigen GPC3 that could prevent HCC development in cirrhotic liver.
PMID: 30018715 [PubMed]
Source: American Journal of Translational Research - Category: Research Tags: Am J Transl Res Source Type: research
More News: Cancer | Cancer & Oncology | Cancer Vaccines | Carcinoma | Hepatitis | Hepatitis B | Hepatitis Vaccine | Hepatocellular Carcinoma | Liver | Liver Cancer | Nanotechnology | Nutrition | Research | Urology & Nephrology | Vaccines